Center for Vaccine Innovation and Access, PATH, Seattle, Washington, USA.
Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S165-S171. doi: 10.1093/cid/ciaa483.
Most vaccines in the Expanded Program on Immunization are universal childhood vaccines (eg, measles and rotavirus vaccines). Other vaccines such as typhoid conjugate (TCV) and Japanese encephalitis vaccines are risk based and only used in countries where populations are at risk of these diseases. However, strategies to introduce risk-based vaccines are becoming complex due to increasing intracountry variability in disease incidence. There is a need to assess whether subnational vaccine strategies are appropriate.
CRITERIA, CHALLENGES, AND BENEFITS: Subnational strategies consider intracountry heterogeneous risk and prioritize vaccination only in those areas that are at risk; there is no intent to introduce the vaccine nationally. The following variables should be considered to determine appropriateness of subnational strategies: disease burden, outbreak potential, treatment availability and costs, cost-effectiveness, and availability of other preventive interventions. We propose criteria for each variable and use a hypothetical country considering TCV introduction to show how criteria are applied to determine if a subnational strategy is appropriate. Challenges include granularity of disease-burden data, political challenges of vaccinating only a portion of a population, and potentially higher costs of introduction. Benefits include targeted reduction of disease burden, increased equity for marginalized populations, and progress on development goals.
In the absence of perfect information at the national level, adopting a subnational vaccine strategy can provide country decision makers with an alternative to national vaccine introduction. Given the changing nature of communicable disease burden, subnational vaccination may be a tool to effectively avert mortality and morbidity while maximizing the use of available health and financial resources.
扩大免疫规划中的大多数疫苗都是通用的儿童疫苗(例如麻疹和轮状病毒疫苗)。其他疫苗,如伤寒结合疫苗(TCV)和乙型脑炎疫苗,是基于风险的,仅在存在这些疾病风险的国家使用。然而,由于疾病发病率在国内的差异不断增加,引入基于风险的疫苗的策略变得越来越复杂。因此,有必要评估国家以下一级的疫苗策略是否合适。
标准、挑战和收益:国家以下一级的策略考虑到了国内的异质风险,并仅在那些有风险的地区优先进行疫苗接种;并没有在全国范围内引入疫苗的意图。为了确定国家以下一级策略的适宜性,应该考虑以下变量:疾病负担、暴发的可能性、治疗的可及性和成本、成本效益以及其他预防干预措施的可及性。我们为每个变量提出了标准,并使用一个考虑引入 TCV 的假设国家来展示如何应用标准来确定国家以下一级的策略是否合适。面临的挑战包括疾病负担数据的粒度、仅为部分人口接种疫苗的政治挑战以及引入疫苗的潜在更高成本。收益包括有针对性地减少疾病负担、增加边缘化人群的公平性以及在发展目标方面取得进展。
在国家一级缺乏完善信息的情况下,采用国家以下一级的疫苗策略可以为国家决策者提供一种替代全国范围引入疫苗的选择。鉴于传染病负担的性质不断变化,国家以下一级的疫苗接种可能是一种有效避免死亡率和发病率的工具,同时最大限度地利用现有的卫生和财政资源。